NTRA Pengajuan SEC - Natera, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1604821

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Natera, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 8, 2025	EX-10.1	Amended Compensation Program for Non-Employee Directors Exhibit 10.1 Natera, Inc. Compensation Program for Non-Employee Directors Amended Effective as of June 2025 A.Annual Retainer Compensation: Each non-employee director will be granted an “annual retainer” representing such director’s annual retainer compensation calculated as set forth in the table below*, in the form of fully vested RSUs covering shares of the Company’s Common Stock. Such fully ve
August 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Natera, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
August 7, 2025	EX-99.2	August 7, 2025 Natera, Inc. Q2’2025 Earnings Presentation Exhibit 99.2 August 7, 2025 Natera, Inc. Q2’2025 Earnings Presentation This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our re
August 7, 2025	EX-99.1	Natera, Inc. Consolidated Balance Sheets (in thousands, except shares) Exhibit 99.1 Natera Reports Second Quarter 2025 Financial Results AUSTIN, Texas, August 7, 2025 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights · Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4
June 18, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
June 18, 2025	EX-10.1	Amended and Restated 2015 Equity Incentive Plan, as amended. Exhibit 10.1 Natera, Inc. 2015 Equity Incentive Plan (Originally Adopted on June 18, 2015, Amended and Restated on March 7, 2024, and Further Amended on March 6, 2025) Natera, Inc. 2015 Equity Incentive Plan ARTICLE 1. INTRODUCTION. The Plan was originally adopted by the Board and effective on June 18, 2015, although no awards were granted prior to the IPO Date. The Plan as most recently amended a
May 9, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 8, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number) (
May 8, 2025	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports First Quarter 2025 Financial Results AUSTIN, Texas, May 8, 2025 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights · Generated total revenues of $501.8 million in the first quarter of 2025, compared
May 8, 2025	EX-99.2	May 8, 2025 Natera, Inc. Q1’2025 Earnings Presentation This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained Exhibit 99.2 May 8, 2025 Natera, Inc. Q1’2025 Earnings Presentation This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimburs
April 24, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 24, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 12, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
February 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37
February 28, 2025	EX-10.2(9)	Ninth Amendment to Supply Agreement, dated March 11, 2024, by and between the Registrant and Illumina, Inc. Exhibit 10.2.9 THE SYMBOL “[*]” DENOTES PLACES WHERE certain identified information has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential. NINTH AMENDMENT TO SUPPLY AGREEMENT This Ninth Amendment to Supply Agreement (the “Ninth Amendment”) is effective as of the date last signed below (the “Ninth Amendment Date”) be
February 28, 2025	EX-10.13	Amended and Restated Employment Agreement, by and between Registrant and Matthew Rabinowitz, dated November 1, 2024 Exhibit 10.13 Amended and Restated Employment Agreement THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) effective as of November 1, 2024 (the “Effective Date”), by and between MATTHEW RABINOWITZ (the “Executive”) and NATERA, INC., a Delaware corporation (the “Company”). 1.Duties and Scope of Employment. (a)Position. For the term of his employment under this Agreement (the “Employm
February 28, 2025	EX-10.2(10)	Tenth Amendment to Supply Agreement, dated December 31, 2023, by and between the Registrant and Illumina, Inc. Exhibit 10.2.10 THE SYMBOL “[*]” DENOTES PLACES WHERE certain identified information has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential. Confidential TENTH AMENDMENT TO SUPPLY AGREEMENT This Tenth Amendment to Supply Agreement (the “Tenth Amendment”) is effective as of January 10, 2025 (the “Tenth Amendment Date”
February 28, 2025	EX-10.10(2)	Amended Compensation Program for Non-Employee Directors Exhibit 10.10.2 Natera, Inc. Compensation Program for Non-Employee Directors Amended Effective as of January 2025 A.Cash Compensation: Annual cash retainers each paid quarterly, in arrears.* 1. Retainer for each non-employee member of the Board: $60,000 2. Additional retainer for Lead Independent Director: $40,000 3. Additional retainer for Chair of Audit Committee: $25,000 4. Additional retainer
February 28, 2025	S-8	As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	EX-FILING FEES	Filing Fee Table Calculation of Filing Fee Tables S-8 Natera, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2015 Employee Stock Purchase Plan Common Stock, $0.0001 par value per share Other 880,000 $ 130.713 $ 115,027,440.00 0.0
February 28, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 Insider Trading Policy Natera, Inc. Insider Trading Policy (as of February 24, 2023) Table of Contents Page Introduction‌1 A.Legal Prohibitions on Insider Trading‌1 B.Detection and Prosecution of Insider Trading‌1 C.Penalties for Violation of Insider Trading Laws and This Policy‌2 D.ITP Officer‌2 E.Reporting Violations‌2 F.Personal responsibility‌3 Persons and Transactions Covered by
February 27, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
February 27, 2025	EX-99.2	February 27, 2025 Natera, Inc. Q4’2024 Earnings Presentation Confidential draft Exhibit 99.2 February 27, 2025 Natera, Inc. Q4’2024 Earnings Presentation Confidential draft This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and lau
February 27, 2025	EX-99.1	Natera, Inc. Consolidated Balance Sheets (in thousands, except shares) Exhibit 99.1 Natera Reports Fourth Quarter and Full Year 2024 Financial Results AUSTIN, Texas, February 27, 2025 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights · Generated total revenues of $476.1 million in the fourth qua
January 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numb
January 13, 2025	EX-99.1	Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlook Additional business updates Exhibit 99.1 Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlook Additional business updates to be presented by Natera at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 AUSTIN, Texas, January 12, 2025 — Nat
December 6, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numb
November 14, 2024	SC 13G/A	NTRA / Natera, Inc. / ALGER ASSOCIATES INC - NATERA, INC. Passive Investment SC 13G/A 1 d890082dsc13ga.htm NATERA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Natera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 632307104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
November 12, 2024	EX-99.1	Natera, Inc. Consolidated Balance Sheets (in thousands, except shares) Exhibit 99.1 Natera Reports Third Quarter 2024 Financial Results AUSTIN, Texas, November 12, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights · Generated total revenues of $439.8 million in the third quarter of 2024, co
November 12, 2024	EX-99.2	Not for reproduction or further distribution. 10 Completed analysis of randomized, phase III CRC trial First - of - its - kind analysis from CALGB (Alliance)/SWOG 80702 trial of >1K patients; presenting results at ASCO GI in Jan. 2025 Study Highlight Exhibit 99.2 Natera, Inc. Investor presentation Q3 2024 Earnings Call Nov. 12, 2024 1 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this presentation, including statements regarding our market oppor
November 12, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
August 9, 2024	EX-10.1	Amended and Restated Employment Agreement, by and between Registrant and Steve Chapman, dated August 1, 2024 Exhibit 10.1 Amended and Restated Employment Agreement THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) effective as of August 1, 2024 (the “Effective Date”), by and between STEVE CHAPMAN (the “Executive”) and NATERA, INC., a Delaware corporation (the “Company”). 1. Duties and Scope of Employment. (a)Position. Effective as of the Commencement Date (the “Employment”), the Company ag
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00
August 8, 2024	EX-99.2	Natera, Inc. Investor presentation Q2 2024 Earnings Call August 8, 2024 Exhibit 99.2 Natera, Inc. Investor presentation Q2 2024 Earnings Call August 8, 2024 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this presentation, including statements regarding our market opport
August 8, 2024	EX-99.1	Natera, Inc. Consolidated Balance Sheets (in thousands, except shares) Exhibit 99.1 Natera Reports Second Quarter 2024 Financial Results AUSTIN, Texas, August 8, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights · Generated total revenues of $413.4 million in the second quarter of 2024, compare
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
July 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Natera, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
July 16, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Natera, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(4) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(4) Equity Common Stock, par value $0.0
July 16, 2024	S-8	As filed with the Securities and Exchange Commission on July 15, 2024 As filed with the Securities and Exchange Commission on July 15, 2024 Registration No.
June 18, 2024	EX-10.1	Amended and Restated 2015 Equity Incentive Plan   Exhibit 10.1    Natera, Inc.   2015 Equity Incentive Plan   (Originally Adopted on June 18, 2015, Amended and Restated on March 7, 2024)       Natera, Inc. 2015 Equity Incentive Plan   ARTICLE 1. INTRODUCTION.   The Plan was originally adopted by the Board and effective on June 18, 2015, although no awards were granted prior to the IPO Date. The Plan as most recently amended and restated was ado
June 18, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
June 7, 2024	SC 13G/A	NTRA / Natera, Inc. / JPMORGAN CHASE & CO - FILING NATERA, INC. Passive Investment SC 13G/A 1 NATERAINC.htm FILING NATERA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* NATERA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 632307104 (CUSIP Number) May 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the a
June 5, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
May 10, 2024	EX-10.1	Executive Severance Plan Exhibit 10.1 EXECUTIVE SEVERANCE PLAN 1.Purpose of the Plan The purpose of the Executive Severance Plan (the “Plan”) is to provide for the payment of severance benefits to certain eligible employees of the Company in the event such employees are subject to certain qualifying employment terminations. This Plan shall supersede any and all prior separation, severance and salary continuation arrangeme
May 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0
May 10, 2024	EX-10.2	Amendment 2 to Amended and Restated Employment Agreement, by and between Registrant and Steve Chapman, dated April 22, 2024 Exhibit 10.2 Amendment No. 2 to Amended and Restated Employment Agreement THIS Amendment No. 2 (the “Amendment”) to the Amended and Restated Employment Agreement, effective as of April 22, 2024 (the “Effective Date”), by and between Steve Chapman (the “Executive”) and Natera, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, the Employee and the Company are parties to an Amended and
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number) (
May 9, 2024	EX-99.2	Natera, Inc. Investor presentation Q1 2024 Earnings Call May 9, 2024 Exhibit 99.2 Natera, Inc. Investor presentation Q1 2024 Earnings Call May 9, 2024 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportuni
May 9, 2024	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports First Quarter 2024 Financial Results AUSTIN, Texas, May 9, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights · Achieved positive cash flow of approximately $3.0 million1 in the first quarter of 20
April 24, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 24, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 1, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Natera, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(4) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(5) Equity Common Stock, par value $0.0
March 1, 2024	S-8	As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No.
February 29, 2024	EX-97.1	Natera, Inc. Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97.1 NATERA, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. Each Executive Officer shall be required to sign and return to the Company the Acknowledgment Form attached here
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37
February 29, 2024	EX-10.2_8	Eighth Amendment to Supply Agreement, dated December 31, 2023, by and between the Registrant and Illumina, Inc Exhibit 10.2.8 THE SYMBOL “[*]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED EIGHT AMENDMENT TO SUPPLY AGREEMENT This Eighth Amendment to Supply Agreement (the “Eighth Amendment”) is effective as of the date last signed below (the “Eighth
February 28, 2024	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Fourth Quarter and Full Year 2023 Financial Results AUSTIN, Texas, February 28, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported its financial results for the fourth quarter and year ended December 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $311.1 million in the fourth quarte
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Natera, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
February 28, 2024	EX-99.2	Natera, Inc. Investor presentation Q4 and Full Year 2023 Earnings Call February 28, 2024 Exhibit 99.2 Natera, Inc. Investor presentation Q4 and Full Year 2023 Earnings Call February 28, 2024 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding o
February 14, 2024	SC 13G/A	NTRA / Natera, Inc. / ALGER ASSOCIATES INC - NATERA, INC. Passive Investment SC 13G/A 1 d117525dsc13ga.htm NATERA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Natera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 632307104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 13, 2024	SC 13G/A	NTRA / Natera, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01509-naterainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Natera Inc Title of Class of Securities: Common Stock CUSIP Number: 632307104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs
January 23, 2024	SC 13G/A	NTRA / Natera, Inc. / JPMORGAN CHASE & CO - FILING NATERA, INC. Passive Investment SC 13G/A 1 NATERAINC.htm FILING NATERA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* NATERA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 632307104 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check
January 22, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numb
January 22, 2024	EX-99.1	Natera Acquires Reproductive Health Assets from Invitae Exhibit 99.1 Natera Acquires Reproductive Health Assets from Invitae AUSTIN, Texas, Jan. 22, 2024 — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical genetics company, certain assets relating to Invitae’s non-invasive prenatal screening and carrier screening business. Natera has made an u
January 9, 2024	EX-99.1	Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues 2023 revenues are expected to be approximately $20 million above top end of guidance Exhibit 99.1 Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues 2023 revenues are expected to be approximately $20 million above top end of guidance AUSTIN, Texas, Jan. 9, 2024 — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expects
January 9, 2024	EX-99.2	Natera, Inc. Investor presentation J.P. Morgan Healthcare Conference January 9, 2024 Exhibit 99.2 Natera, Inc. Investor presentation J.P. Morgan Healthcare Conference January 9, 2024 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our m
January 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numbe
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
November 8, 2023	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Third Quarter 2023 Financial Results AUSTIN, Texas, November 8, 2023 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $268.3 million in the third quarter of 2023, compared to $210.6
November 8, 2023	EX-99.2	Natera, Inc. Investor presentation Third Quarter 2023 Earnings Call November 8, 2023 Confidential Draft Exhibit 99.2 Natera, Inc. Investor presentation Third Quarter 2023 Earnings Call November 8, 2023 Confidential Draft Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including stateme
November 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numb
September 7, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
September 7, 2023	EX-99.2	Natera Announces Pricing of $250 Million Follow-On Offering Exhibit 99.2 NEWS RELEASE Natera Announces Pricing of $250 Million Follow-On Offering AUSTIN, Texas, September 6, 2023—Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share. Closing of the offering is expected to occur on Sept
September 7, 2023	424B5	4,550,000 Shares COMMON STOCK TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-274372 4,550,000 Shares COMMON STOCK We are offering 4,550,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol “NTRA.” On September 6, 2023, the last reported sale price of our common stock on Nasdaq was $58.00 per share. Investing in our common stock inv
September 7, 2023	EX-1.1	Underwriting Agreement dated as of September 6, 2023, by and among Natera, Inc. and Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC, and Piper Sandler & Co., as representatives of the underwriters named therein. Exhibit 1.1 Execution Version 4,550,000 Shares NATERA, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT September 6, 2023 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Goldman Sachs & Co.
September 7, 2023	EX-FILING FEES	Calculation of Filing Fee Tables 424(b)(5) (Form Type) Natera, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Natera, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.000
September 7, 2023	EX-99.1	Natera Launches Proposed Follow-On Offering Exhibit 99.1 NEWS RELEASE Natera Launches Proposed Follow-On Offering AUSTIN, Texas, September 6, 2023—Natera, Inc. (Nasdaq: NTRA) (“Natera”), a global leader in cell-free DNA (cfDNA) testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an ad
September 6, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Natera, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.0
September 6, 2023	S-3ASR	As filed with the Securities and Exchange Commission on September 6, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 6, 2023 Registration No.
August 4, 2023	EX-10.1	Second Amendment to Employment Agreement, by and between Registrant and Matthew Rabinowitz, dated April 19, 2023. Exhibit 10.1 Second Amendment to Employment Agreement THIS Second Amendment (the “Amendment”) to the Amended Employment Agreement dated June 7, 2007 is entered into as of April 19, 2023 (the “Effective Date”), by and between Matthew Rabinowitz (the “Employee”) and Natera, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, the Employee and the Company entered into an Amended Employment
August 4, 2023	EX-10.2	Amended Compensation Program for Non-Employee Directors. Exhibit 10.2 Natera, Inc. Compensation Program for Non-Employee Directors Amended Effective as of June 9, 2023 A.Cash Compensation: Annual cash retainers each paid quarterly, in arrears. 1. Retainer for each non-employee member of the Board: $50,000 2. Additional retainer for Lead Independent Director: $35,000 3. Additional retainer for Chair of Audit Committee: $20,000 4. Additional retainer for
August 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00
August 3, 2023	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Second Quarter 2023 Financial Results AUSTIN, Texas, August 3, 2023 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 mill
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Natera, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
August 3, 2023	EX-99.2	Natera, Inc. Investor presentation Second Quarter 2023 Earnings Call August 3, 2023 Exhibit 99.2 Natera, Inc. Investor presentation Second Quarter 2023 Earnings Call August 3, 2023 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our ma
June 15, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0
May 10, 2023	EX-10.1	Amended Compensation Program for Non-Employee Directors. Exhibit 10.1 Natera, Inc. Compensation Program for Non-Employee Directors Amended Effective as of March 16, 2023 A.Cash Compensation: Annual cash retainers each paid quarterly, in arrears. 1. Retainer for each non-employee member of the Board: $45,000* 2. Additional retainer for Lead Independent Director: $35,000 3. Additional retainer for Chair of Audit Committee: $20,000 4. Additional retainer f
May 9, 2023	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports First Quarter 2023 Financial Results AUSTIN, Texas, May 9, 2023 — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 million in the first q
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Natera, Inc. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number) (
May 9, 2023	EX-99.2	Natera, Inc. Investor presentation First Quarter 2023 Earnings Call May 9, 2023 Exhibit 99.2 Natera, Inc. Investor presentation First Quarter 2023 Earnings Call May 9, 2023 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market
April 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 Natera, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
April 20, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 20, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Natera, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
March 1, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37
March 1, 2023	S-8	As filed with the Securities and Exchange Commission on March 1, 2023 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.
March 1, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 tmb-20230301xexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Natera, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(4) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amo
February 28, 2023	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Fourth Quarter and Full Year 2022 Financial Results AUSTIN, Texas, February 28, 2023 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights ●
February 28, 2023	EX-99.2	Natera, Inc. Investor presentation Fourth Quarter 2022 Earnings Call February 28, 2023 Exhibit 99.2 Natera, Inc. Investor presentation Fourth Quarter 2022 Earnings Call February 28, 2023 Not for reproduction or further distribution. Safe harbor statement This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including st
February 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Natera, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 Natera, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
February 14, 2023	SC 13G/A	NTRA / Natera Inc / ALGER ASSOCIATES INC - NATERA, INC. Passive Investment SC 13G/A 1 d433225dsc13ga.htm NATERA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Natera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 632307104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 9, 2023	SC 13G/A	NTRA / Natera Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01475-naterainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Natera Inc. Title of Class of Securities: Common Stock CUSIP Number: 632307104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pur
January 23, 2023	SC 13G/A	NTRA / Natera Inc / JPMORGAN CHASE & CO - FILING NATERA, INC. Passive Investment SC 13G/A 1 NATERAINC.htm FILING NATERA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* NATERA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 632307104 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check
December 6, 2022	POSASR	As filed with the Securities and Exchange Commission on December 6, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 6, 2022 Registration No.
December 6, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 tm2231831d2ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment to Form S-3 (Form Type) Natera, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum
November 16, 2022	EX-99.2	Natera Announces Pricing of Follow-On Offering Exhibit 99.2 NEWS RELEASE Natera Announces Pricing of Follow-On Offering AUSTIN, Texas, November 15, 2022?Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on November 18, 202
November 16, 2022	EX-99.1	Natera Launches Proposed Follow-On Offering Exhibit 99.1 NEWS RELEASE Natera Launches Proposed Follow-On Offering AUSTIN, Texas, November 15, 2022?Natera, Inc. (Nasdaq: NTRA) (?Natera?), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional
November 16, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
November 16, 2022	424B5	11,430,000 Shares COMMON STOCK TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-268391? 11,430,000 Shares COMMON STOCK ? We are offering 11,430,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol ?NTRA.? The last reported sale price of our common stock on November 15, 2022 was $34.17. Investing in our common stock involves risk. See ?Risk Facto
November 16, 2022	EX-FILING FEES	Calculation of Filing Fee Tables 424(b)(5) (Form Type) Natera, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Natera, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.000
November 16, 2022	EX-1.1	Underwriting Agreement dated as of November 15, 2022, among Natera, Inc. and Morgan Stanley & Co. LLC, Cowen and Company, LLC, and SVB Securities LLC, as representatives of the underwriters named therein. EX-1.1 2 tm2230578d8ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 11,430,000 Shares NATERA, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT November 15, 2022 Morgan Stanley & Co. LLC Cowen and Company, LLC SVB Securities LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company,
November 15, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 tm2230578d4ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Natera, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount
November 15, 2022	S-3ASR	As filed with the Securities and Exchange Commission on November 15, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 15, 2022 Registration No.
November 9, 2022	EX-10.2	First Amendment to Lease Agreement dated January 26, 2016, by and between NSTX, Inc. and Karlin McCallen Pass, LLC. Exhibit 10.2 ? FIRST AMENDMENT TO LEASE ? This FIRST AMENDMENT TO LEASE (this Amendment) is made and entered into as of January 6, 2016, by and between KARLIN MCCALLEN PASS, LLC, a Delaware limited liability company (Landlord), and NSTX, INC., a Delaware corporation (Tenant). ? BACKGROUND: ? A. On September 24, 2015, Landlord and Tenant entered into a Lease (the Lease) for approximately 93,967 squ
November 9, 2022	EX-10.4	Third Amendment to Lease Agreement dated December 29, 2021, by and between NSTX, Inc. and 13011 McCallen Pass, LLC. ? Exhibit 10.4 ? THIRD AMENDMENT TO LEASE AGREEMENT ? THIS THIRD AMENDMENT TO LEASE AGREEMENT (this "Third Amendment") is made as of December 29 , 2021, by and between 13011 MCCALLEN PASS, LLC, a Delaware limited liability company ("Landlord"), and NSTX, INC., a Delaware corporation ("Tenant"). ? RECITALS ? A.Landlord and Tenant are now parties to that certain Lease Agreement dated as of September
November 9, 2022	EX-10.3	Second Amendment to Lease Agreement dated March 10, 2021, by and between NSTX, Inc. and KCP Parmer 3.2 Fee Owner, LLC. Exhibit 10.3 ? SECOND AMENDMENT TO LEASE AGREEMENT ? THIS SECOND AMENDMENT TO LEASE AGREEMENT (this "Amendment") is made as of the 10 day of March, 2021(the "Effective Date"), by and between KCP PARMER 3.2 FEE OWNER, LLC, a Delaware limited liability company ("Landlord"), and NSTX, INC., a Delaware corporation ("Tenant," together with Landlord, sometimes collectively referred to herein as the "Par
November 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
November 9, 2022	EX-10.1	Lease Agreement dated September 24, 2015, by and between NSTX, Inc. and Karlin McCallen Pass, LLC. Exhibit 10.1 ? LEASE AGREEMENT BETWEEN KARLIN MCCALLEN PASS, LLC, AS LANDLORD, AND NSTX, INC., AS TENANT DATED SEPTEMBER 24, 2015 ? AUSTIN, TEXAS ? ? ? ? BASIC LEASE INFORMATION ? ? ? Lease Date: September , 2015 Landlord: ? Karlin McCallen Pass, LLC, a Delaware limited liability company Tenant: ? NSTX, Inc., a Delaware corporation Premises: ? Approximately 93,967 rentable square feet, consisting
November 8, 2022	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Third Quarter 2022 Financial Results AUSTIN, Texas, November 8, 2022 /PRNewswire/ ? Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022. Recent Strategic and Financial Highlights ? Generated total revenues of $210.6 million in the third quarter of 2022 compared to $158.1 m
November 8, 2022	EX-99.2	Natera, Inc. Investor presentation Third Quarter 2022 Earnings Call November 8 , 2022 Exhibit 99.2 Natera, Inc. Investor presentation Third Quarter 2022 Earnings Call November 8 , 2022 This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our proposed products and
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numb
August 15, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numbe
August 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
August 5, 2022	EX-10.1	Amended Employment Agreement, by and between Registrant and Daniel Rabinowitz, dated June 7, 2007. Exhibit 10.1 Amended Employment Agreement This Agreement is entered into as of June 7, 2007, by and between Daniel Rabinowitz (the "Employee") and Gene Security Network, Inc., a Delaware corporation (the "Company"). This Agreement amends and restates in its entirety the Employment Agreement entered into between the parties hereto on January 27, 2007. 1. Duties and Scope of Employment. (a)Position.
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
August 4, 2022	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Second Quarter 2022 Financial Results AUSTIN, Texas, August 4, 2022 /PRNewswire/ ? Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights ? Generated total revenues of $1
August 4, 2022	EX-99.2	Natera, Inc. Investor presentation Second Quarter 2022 Earnings Call August 4, 2022 Exhibit 99.2 Natera, Inc. Investor presentation Second Quarter 2022 Earnings Call August 4, 2022 This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our proposed products and la
June 1, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
May 6, 2022	EX-10.1	Amendment No. 1 to Amended and Restated Employment Agreement Exhibit 10.1 ? FINAL Amendment No. 1 to Amended and Restated Employment Agreement ? THIS Amendment No. 1 (the ?Amendment?) to the Amended and Restated Employment Agreement, effective as of May 4, 2022 (the ?Effective Date?), by and between Steve Chapman (the ?Executive?) and Natera, Inc., a Delaware corporation (the ?Company?). ? RECITALS WHEREAS, the Employee and the Company entered into an Amend
May 6, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 5, 2022	EX-99.2	Natera, Inc. Investor presentation First Quarter 2022 Earnings Call May 5, 2022 Exhibit 99.2 Natera, Inc. Investor presentation First Quarter 2022 Earnings Call May 5, 2022 2 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our mark
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number) (
May 5, 2022	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports First Quarter 2022 Financial Results AUSTIN, Texas, May 5, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights ● Generated total revenues of $194.1
April 15, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
April 13, 2022	DEF 14A	Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 13, 2022, Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule
April 13, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-
March 14, 2022	EX-99.1	Natera Executives and Board to Take Pay in Stock Instead of Cash Leadership, Board to Exchange Cash Compensation for Shares Exhibit 99.1 Natera Executives and Board to Take Pay in Stock Instead of Cash Leadership, Board to Exchange Cash Compensation for Shares AUSTIN, Texas, March 14, 2022 ? Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that its executive leaders and board of directors have unanimously agreed on a compensation change that will see them take company stock instead of th
March 14, 2022	EX-10.1	Amended and Restated Compensation Program for Non-Employee Directors. Exhibit 10.1 Natera, Inc. Amended and Restated Compensation Program for Non-Employee Directors Effective as of March 13, 2022 A. Cash Compensation: Annual cash retainers each paid quarterly, in arrears. 1. Retainer for each non-employee member of the Board: $ 45,000 2. Additional retainer for Lead Independent Director: $ 35,000 3. Additional retainer for Chair of Audit Committee: $ 20,000 4. Addit
March 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
February 25, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 tmb-20220224xexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Natera, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(4) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amo
February 25, 2022	S-8	As filed with the Securities and Exchange Commission on February 25, 2022 As filed with the Securities and Exchange Commission on February 25, 2022 Registration No.
February 25, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
February 24, 2022	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Fourth Quarter and Full Year 2021 Financial Results AUSTIN, Texas, February 24, 2022 /PRNewswire/ ? Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights ?
February 24, 2022	EX-99.2	Natera, Inc. Investor presentation Fourth Quarter 2021 Earnings Call Exhibit 99.2 Natera, Inc. Investor presentation Fourth Quarter 2021 Earnings Call 2 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportun
February 24, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
February 14, 2022	SC 13G/A	NTRA / Natera Inc / ALGER ASSOCIATES INC - NATERA, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Natera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 632307104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i
February 10, 2022	SC 13G/A	NTRA / Natera Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Natera Inc. Title of Class of Securities: Common Stock CUSIP Number: 632307104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13
January 24, 2022	SC 13G	NTRA / Natera Inc / JPMORGAN CHASE & CO - FILING NATERA, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NATERA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 632307104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
December 23, 2021	CORRESP	Via EDGAR Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 December 23, 2021 Attention: Nudrat Salik Terence O?Brien Re: Natera, Inc. Form 10-K for the Year Ended December 31, 2020 Form 10-Q for the Period Ended September 30, 2021 Response filed November 12, 2021 Response filed December 8, 2021 File No. 0
December 8, 2021	CORRESP	Via EDGAR Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Nudrat Salik Terence O?Brien Re: Natera, Inc. Form 10-K for the Year Ended December 31, 2020 Form 10-Q for the Period Ended September 30, 2021 Response dated November 12, 2021 File No. 001-37478 Ladies and Gentlemen: Reference is made t
November 12, 2021	CORRESP	Natera, Inc. Natera, Inc. November 12, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Nudrat Salik Terence O?Brien Re: Natera, Inc. Form 10-K for the Year Ended December 31, 2020 Form 10-Q for the Period Ended June 30, 2021 File No. 001-37478 Ladies and Gentlemen: Reference is made to the c
November 5, 2021	EX-3.1	Amended and Restated Bylaws of the Registrant, effective as of November 3, 2021 Exhibit 3.1 Amended and Restated Bylaws Natera, Inc. (as of November 3, 2021) ? ? ? GDSVF&H\7706247.2 ? Table of Contents Page Article I Stockholders?1 1.1Place of Meetings?1 1.2Annual Meeting?1 1.3Special Meetings?1 1.4Notice of Meetings?1 1.5Voting List?1 1.6Quorum?1 1.7Adjournments?2 1.8Voting and Proxies?2 1.9Action at Meeting?2 1.10Nomination of Directors?2 1.11Notice of Business at Annual Me
November 5, 2021	EX-10.1	Seventh Amendment to Supply Agreement, dated October 7, 2021, by and between the Registrant and Illumina, Inc. THE SYMBOL ?[*]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED ? Confidential ?Exhibit 10.
November 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
November 4, 2021	EX-99.2	Investor presentation Natera, Inc. Q3 2021 e arnings call Exhibit 99.2 Investor presentation Natera, Inc. Q3 2021 e arnings call 2 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our p
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numb
November 4, 2021	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Third Quarter 2021 Financial Results AUSTIN, Texas, November 4, 2021 /PRNewswire/ ? Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights ? Generated total revenues
September 10, 2021	S-3ASR	As filed with the Securities and Exchange Commission on September 10, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 10, 2021 Registration No.
August 6, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
August 5, 2021	EX-99.2	Natera, Inc. Investor presentation Q2 2021 Earnings call 2 Not for reproduction or further distribution. This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements o EX-99.2 3 tm2124237d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Natera, Inc. Investor presentation Q2 2021 Earnings call 2 Not for reproduction or further distribution. This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statement
August 5, 2021	EX-99.1	Test Volume Summary EX-99.1 2 tm2124237d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Natera Reports Second Quarter 2021 Financial Results AUSTIN, Texas, August 5, 2021 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent business progress and financial outlook. Recent Acco
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
July 22, 2021	EX-1.1	Underwriting Agreement dated as of July 21, 2021, among Natera, Inc. and Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and SVB Leerink LLC, as representatives of the underwriters named therein. EX-1.1 2 tm2122790d2ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 4,500,000 Shares NATERA, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT July 21, 2021 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC Cowen and Company, LLC SVB Leerink LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Gol
July 22, 2021	424B5	CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-258047? CALCULATION OF REGISTRATION FEE ? ? Title of Each Class of Securities to be Registered ? ? Amount to be registered(1) ? ? Maximum Offering Price Per Share ? ? Maximum Aggregate Offering Price ? ? Amount of Registration Fee(2) ? Common Stock, $0.0001 par value ? ? 5,175,000 ? ? ? $ 113.00 ? ? ? ? $ 584,775,000 ? ? ? ? $
July 22, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2021 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
July 22, 2021	EX-99.2	Natera Announces Pricing of Follow-On Offering Exhibit 99.2 NEWS RELEASE Natera Announces Pricing of Follow-On Offering AUSTIN, Texas, July 21, 2021?Natera, Inc. (Nasdaq: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $113.00 per share. Closing of the offering is expected to occur on July 26, 2021, s
July 22, 2021	EX-99.1	Natera Launches Proposed Follow-On Offering Exhibit 99.1 NEWS RELEASE Natera Launches Proposed Follow-On Offering AUSTIN, Texas, July 20, 2021?Natera, Inc. (Nasdaq: NTRA) (?Natera?), a pioneer and global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an ad
July 20, 2021	S-3ASR	As filed with the Securities and Exchange Commission on July 20, 2021 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on July 20, 2021 Registration No.
July 20, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2021 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
July 20, 2021	EX-99.1	Natera Reports Preliminary Second Quarter 2021 Results Record Growth in Revenues and Tests Processed; Women’s Health Business Cash Flow Breakeven Exhibit 99.1 NEWS RELEASE Natera Reports Preliminary Second Quarter 2021 Results Record Growth in Revenues and Tests Processed; Women?s Health Business Cash Flow Breakeven AUSTIN, Texas, July 19, 2021?Natera, Inc. (Nasdaq: NTRA) (?Natera? or the ?Company?), a pioneer and global leader in cell-free DNA testing, today reported preliminary results for the quarter ended June 30, 2021 for volume and re
May 28, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
May 10, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2021 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number) (
May 10, 2021	EX-10.2	Amended Employment Agreement, by and between Registrant and Matthew Rabinowitz, dated May 9, 2021. Exhibit 10.2 Amendment to Employment Agreement THIS Amendment (the ?Amendment?) to the Amended Employment Agreement dated June 7, 2007 (the ?Agreement?) is entered into as of May 9, 2021 (the ?Effective Date?), by and between Matthew Rabinowitz (the ?Employee?) and Natera, Inc., a Delaware corporation (the ?Company?). RECITALS WHEREAS, the Employee and the Company entered into the Agreement dated
May 7, 2021	10-Q	Quarterly Report - 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number) (
May 6, 2021	EX-99.2	Investor Presentation. Exhibit 99.2 Natera, Inc. Investor presentation May 2021 Q1 2021 earnings call Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding the market opportunity, products and launch schedu
May 6, 2021	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports First Quarter 2021 Financial Results AUSTIN, Texas, May 6, 2021 /PRNewswire/ ? Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2021 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights ? Generated total revenu
April 13, 2021	DEF 14A	Definitive Proxy Statement on Schedule 14A, filed on April 13, 2021 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???????? ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitte
April 13, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 2, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 2, 2021 Registration No.
February 26, 2021	EX-4.3	Description of Common Stock Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, par value $0.0001 per share, of Natera, Inc. (?us,? ?our,? ?we,? or the ?Company?), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), summarizes certain in
February 26, 2021	10-K	Annual Report - 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
February 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
February 25, 2021	EX-99.2	Natera, Inc. Investor presentation February 2021 Q4 2020 earnings call Exhibit 99.2 Natera, Inc. Investor presentation February 2021 Q4 2020 earnings call 2 Not for reproduction or further distribution. This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding the market opport
February 25, 2021	EX-99.1	Test Volume Summary EX-99.1 2 tm217945d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Natera Reports Fourth Quarter and Year 2020 Financial Results SAN CARLOS, Calif., February 25, 2021 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided an update on recent business progress. Rece
February 16, 2021	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Natera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 632307104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Natera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December 31, 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Natera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 632307104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Natera Inc. Title of Class of Securities: Common Stock CUSIP Number: 632307104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13
November 23, 2020	EX-99.1	Natera Appoints Dr. Monica Bertagnolli to its Board of Directors Former president and current board member of ASCO brings deep oncology expertise and leadership Exhibit 99.1 Natera Appoints Dr. Monica Bertagnolli to its Board of Directors Former president and current board member of ASCO brings deep oncology expertise and leadership SAN CARLOS, Calif., Nov. 19, 2020 - Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. Monica Bertagnolli to its board of directors. “We are delighted t
November 23, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
November 6, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
November 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numb
November 5, 2020	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Third Quarter 2020 Financial Results SAN CARLOS, Calif., November 5, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. Recent Accomplishments & Highlights ● Processed approximately 262,00
November 5, 2020	EX-99.2	1 Not for reproduction or further distribution. Natera, Inc. Third Quarter 2020 Earnings Presentation November 5, 2020 Exhibit 99.2 1 Not for reproduction or further distribution. Natera, Inc. Third Quarter 2020 Earnings Presentation November 5, 2020 2 Not for reproduction or further distribution. Safe harbor statement This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained
September 11, 2020	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be registered(1) Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2)(3) Common Stock, $0.0001 par value 4,791,665 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
September 11, 2020	EX-99.1	Natera Launches Proposed Follow-On Offering Exhibit 99.1 NEWS RELEASE Natera Launches Proposed Follow-On Offering SAN CARLOS, Calif., September 9, 2020—Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $37,5
September 11, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Num
September 11, 2020	EX-99.2	Natera Announces Pricing of Follow-On Offering Exhibit 99.2 NEWS RELEASE Natera Announces Pricing of Follow-On Offering SAN CARLOS, Calif., September 10, 2020—Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,166,666 shares of its common stock at a price to the public of $60.00 per share. Closing of the offering is expected to occur on September 15, 2020,
September 11, 2020	EX-1.1	Underwriting Agreement dated as of September 10, 2020, among Natera, Inc. and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Cowen and Company, LLC and SVB Leerink LLC as representatives of the underwriters named therein. Exhibit 1.1 4,166,666 Shares NATERA, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT September 10, 2020 September 10, 2020 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Cowen and Company, LLC SVB Leerink LLC c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company
September 9, 2020	S-3ASR	- S-3ASR Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on September 9, 2020 Registration No.
August 7, 2020	EX-10.1	Sixth Amendment to Supply Agreement, dated May 8, 2020, by and between Registrant and Illumina, Inc. Exhibit 10.1 THE SYMBOL “[*]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SIXTH AMENDMENT TO SUPPLY AGREEMENT This Sixth Amendment to Supply Agreement (the “Sixth Amendment”) is effective as of the date last signed below (the “Sixth Amend
August 7, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00
August 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
August 5, 2020	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Second Quarter 2020 Financial Results SAN CARLOS, Calif., August 5, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. Recent Accomplishments & Highlights · Processed approximately 234,100 tes
August 5, 2020	EX-99.2	1 Not for reproduction or further distribution. Natera, Inc. Second Quarter 2020 Earnings Presentation August 5, 2020 Exhibit 99.2 1 Not for reproduction or further distribution. Natera, Inc. Second Quarter 2020 Earnings Presentation August 5, 2020 2 Not for reproduction or further distribution. Safe harbor statement This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained i
June 3, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number)
May 12, 2020	8-K	Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number) (
May 8, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0
May 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number) (
May 6, 2020	EX-99.2	1 Not for reproduction or further distribution. Natera, Inc. First quarter 2020 Earnings presentation May 6, 2020 2 Not for reproduction or further distribution. Safe harbor statement This presentation contains forward - looking statements under the Exhibit 99.2 1 Not for reproduction or further distribution. Natera, Inc. First quarter 2020 Earnings presentation May 6, 2020 2 Not for reproduction or further distribution. Safe harbor statement This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in th
May 6, 2020	EX-99.1	Test Volume Summary EX-99.1 2 tm2018778d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Natera Reports First Quarter 2020 Financial Results SAN CARLOS, Calif., May 6, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent business progress. Recent Accomplishments & Highlig
April 16, 2020	EX-99.1	Natera Prices $250 Million Convertible Senior Notes Due 2027 Exhibit 99.1 Natera Prices $250 Million Convertible Senior Notes Due 2027 SAN CARLOS, Calif., April 13, 2020 – Natera, Inc. (NASDAQ: NTRA) today announced that it has priced $250 million aggregate principal amount of convertible senior notes due 2027 (the “notes”). The notes will be sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Natera al
April 16, 2020	EX-4.1	Indenture (including form of Note) with respect to the Company’s 2.25% Convertible Senior Notes due 2027, dated as of April 16, 2020, between the Registrant and Wilmington Trust, National Association, as trustee Exhibit 4.1 NATERA, INC. AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of April 16, 2020 2.25% Convertible Senior Notes due 2027 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01 . Definitions 1 Section 1.02 . References to Interest 13 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01 . Designation and Amount 13 Section 2.0
April 16, 2020	DEF 14A	Definitive Proxy Statement on Schedule 14A, filed on April 16, 2020 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 16, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
April 16, 2020	DEFA14A	NTRA / Natera, Inc. DEFA14A - - DEFA14A DEFA14A 1 a20-20373defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commiss
April 13, 2020	EX-99.1	Natera Announces Preliminary First Quarter 2020 Financial Results Quarterly unit growth largest in company history EX-99.1 2 tm2015715d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE Natera Announces Preliminary First Quarter 2020 Financial Results Quarterly unit growth largest in company history SAN CARLOS, Calif., April 13, 2020 - Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced preliminary operational and financial results for the quarter ended March 31,
April 13, 2020	EX-99.2	Natera to Offer $250 Million Convertible Senior Notes Due 2027 Exhibit 99.2 Natera to Offer $250 Million Convertible Senior Notes Due 2027 SAN CARLOS, Calif., April 13, 2020 – Natera, Inc. (NASDAQ: NTRA) today announced that it proposes to offer $250 million aggregate principal amount of convertible senior notes due 2027 (the “notes”), subject to market conditions and other factors. The notes are to be offered and sold to qualified institutional buyers pursua
April 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Number
March 12, 2020	8-K	Termination of a Material Definitive Agreement 8-K 1 tm2012500-18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorp
March 4, 2020	S-8	NTRA / Natera, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on March 3, 2020 Registration No.
March 2, 2020	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37
March 2, 2020	EX-4.3	Description of Common Stock Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, par value $0.0001 per share, of Natera, Inc. (“us,” “our,” “we,” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), summarizes certain in
March 2, 2020	EX-10.5.5	Fifth Amendment to Supply Agreement, dated December 18, 2019, by and between Registrant and Illumina, Inc. Exhibit 10.5.5 Confidential THE SYMBOL “[*]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. FIFTH AMENDMENT TO SUPPLY AGREEMENT This Fifth Amendment to Supply Agreement (the “Fifth Amendment”) is effective as of the date last signed below (
February 26, 2020	EX-99.1	Test Volume Summary Exhibit 99.1 Natera Reports Fourth Quarter and Year 2019 Financial Results SAN CARLOS, Calif., February 26, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and the year ended December 31, 2019 and provided an update on recent business progress. Recent Acc
February 26, 2020	EX-99.2	1 Not for reproduction or further distribution. Natera , Inc. Q4 2019 Earnings call February 26, 2020 Exhibit 99.2 1 Not for reproduction or further distribution. Natera , Inc. Q4 2019 Earnings call February 26, 2020 2 Not for reproduction or further distribution. Safe harbor statement This presentation contains forward - looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentat
February 26, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 tm2010980-18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of in
February 14, 2020	SC 13G/A	NTRA / Natera, Inc. / SEQUOIA TECHNOLOGY PARTNERS XII A DELAWARE L P - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Natera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 632307104 (CUSIP Number) Decem
February 13, 2020	SC 13D/A	NTRA / Natera, Inc. / Sofinnova Venture Partners VIII, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm207776d3sc13da.htm SC 13D/A CUSIP NO. 632307104 13D Page 1 of 15 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Natera, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securiti
February 12, 2020	SC 13G/A	NTRA / Natera, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01437-naterainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Natera Inc Title of Class of Securities: Common Stock CUSIP Number: 632307104 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule purs
February 6, 2020	SC 13G/A	NTRA / Natera, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 4, 2020	SC 13G/A	NTRA / Natera, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) NATERA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 632307104 (CUSIP Number) DECEMBER 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu
November 8, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:
November 8, 2019	EX-10.2	Third Amendment to Application Service Provider Agreement, dated October 18, 2019, by and between Natera, Inc. and DNAnexus, Inc. EX-10.2 3 ntra-20190930ex10273f7c9.htm EX-10.2 Exhibit 10.2 THE SYMBOL “[*]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED CONFIDENTIAL DNAnexus, Inc. Fifth Amendment to the Application Service Provider Agreement dated September 19, 2014 Th
November 8, 2019	EX-10.1	Third Amendment to Credit Agreement, dated as of September 12, 2019, by and between Registrant, Natera International, Inc., NSTX, Inc. and OrbiMed Royalty Opportunities II, LP. Exhibit 10.1 THE SYMBOL “[*]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Execution Copy THIRD AMENDMENT This THIRD AMENDMENT (this “Amendment”) is made and entered into as of September 12, 2019 by NATERA, INC., a Delaware corporation (th
November 6, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numb
November 6, 2019	EX-99.1	Q3 2019 Exhibit 99.1 Natera Reports Third Quarter 2019 Financial Results SAN CARLOS, Calif., November 6, 2019 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2019 and provided an update on recent business progress. Recent Accomplishments & Highlight
November 6, 2019	EX-99.2	Natera, Inc. Q3 2019 Earnings Call November 6, 2019 Exhibit 99.2 Natera, Inc. Q3 2019 Earnings Call November 6, 2019 Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding the market opportunity, products, commercial partners, user expe
October 17, 2019	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.0001 par value 6,571,428 $3 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
October 17, 2019	EX-99.1	Natera Launches Proposed Follow-On Offering Exhibit 99.1 NEWS RELEASE Natera Launches Proposed Follow-On Offering SAN CARLOS, Calif., October 15, 2019—Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $175,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $26,25
October 17, 2019	EX-99.2	Natera Announces Pricing of Follow-On Offering Exhibit 99.2 NEWS RELEASE Natera Announces Pricing of Follow-On Offering SAN CARLOS, Calif., October 16, 2019—Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,714,286 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on October 21, 2019, sub
October 17, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2019 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction of incorporation) (Commission File Numb
October 17, 2019	EX-1.1	Underwriting Agreement dated as of October 16, 2019, among Natera, Inc. and J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named therein. Exhibit 1.1 5,714,286 Shares NATERA, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT October 16, 2019 October 16, 2019 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Natera, Inc., a Delaware corporation (the
October 15, 2019	S-3ASR	NTRA / Natera, Inc. S-3ASR - - S-3ASR Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on October 15, 2019 Registration No.
October 10, 2019	EX-99.1	Natera Inc. Oncology call October 10, 2019 Exhibit 99.1 Natera Inc. Oncology call October 10, 2019 Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding the market opportunity, products, commercial partners, user experience, c
October 10, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a19-1984818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2019 Natera, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37478 01-0894487 (State or other jurisdiction (Commission

NTRA / Natera, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)